Geburtshilfe Frauenheilkd 2017; 77(06): 617
DOI: 10.1055/s-0043-106280
DGGG
Mitteilungen aus der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG)
Georg Thieme Verlag KG Stuttgart · New York

Erlangen, 31.01.2017 – 243rd Statement by the German Society of Gynecology and Obstetrics (DGGG) in Response to the Call for Data on the Safety of PIP Silicone Breast Implants and the Possible Association between Breast Implants and ALCL by the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) of the European Commission

Artikel in mehreren Sprachen: English | deutsch
Birgit Seelbach-Göbel
,
Matthias W. Beckmann
,
Jens-Uwe Blohmer
,
H. Peter Sinn
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
28. Juni 2017 (online)

Silicone breast implants are filled with medical-grade silicone (polydimethylsiloxane: PDMS). PDMS is one of a group of silicon-based organic polymeres with a main chain of alternating silicon and oxygen atoms. The envelope of all implants (including those filled with water) consists of silicon elastomer. The surface of the implant envelope can be smooth or textured, and various processes are used to create the texturing. The silicone envelope may be coated with micropolyurethane (a polymer). Water-filled breast implants also have a silicone envelope.

 
  • References/Literatur

  • 1 Bizjak M, Selmi C, Praprotnik S. et al. Silicone implants and lymphoma: The role of inflammation. J Autoimmun 2015; 65: 64-73
  • 2 Gidengil CA, Predmore Z, Mattke S. et al. Breast implant-associated anaplastic large cell lymphoma: a systematic review. Plast Reconstr Surg 2015; 135: 713-720
  • 3 Hu H, Jacombs A, Vickery K. et al. Chronic biofilm infection in breast implants is associated with an increased T-cell lymphocytic infiltrate: implications for breast implant-associated lymphoma. Plast Reconstr Surg 2015; 135: 319-329
  • 4 Kim B, Predmore ZS, Mattke S. et al. Breast implant-associated anaplastic large cell lymphoma: updated results from a structured expert consultation process. Plast Reconstr Surg Glob Open 2015; 3: e296
  • 5 U.S. Food and Drug Administration. Anaplastic large cell lymphoma (ALCL) in women with breast implants: Preliminary FDA findings and analyses. Online: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htm Last access: 19.03.2016
  • 6 Ramos-Gallardo G, Cuenca-Pardo J, Rodríguez-Olivares E. et al. Breast implant and anaplastic large cell lymphoma meta-analysis. J Invest Surg 2017; 30: 56-65
  • 7 Brody GS, Deapen D, Taylor CR. et al. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg 2015; 135: 695-705
  • 8 Laurent C, Delas A, Gaulard P. et al. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol 2016; 27: 306-314
  • 9 Clemens MW, Medeiros LJ, Butler CE. et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol 2016; 34: 160-168